Pyoderma gangrenosum

1 trials MedDRA PT
1 Registered trials
0 Recruiting
1 Unique sponsors
1 Unique IMPs
1 Commercial trials
Drug classes (ATC)
— ATC code not specified 1
Mechanism of action (INN-stem analysis)
Monoclonal antibody (immune) 1 substance
Phase III: 1

Filter these 1 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 1 trials

Phase III

1 trial
  • InflaRx GmbH Commercial
    VILOBELIMAB
    2023-506250-20-00 8 countries 2023 n=101 Orphan
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
InflaRx GmbH Commercial 1 Phase III 0
New trials by year
2023
1
← All indication landscapes